StreetInsider.com News Articles

Form 424B3 Freenome, Inc.

Tue, 20 Oct 2026 09:26:00 -0400

si-local-file:///var/storage/secattach/20261020/27208106.html

Form 8-K Freenome, Inc. For: Oct 20

Tue, 20 Oct 2026 08:53:00 -0400

si-local-file:///var/storage/secattach/20261020/27207439.html

Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option

Tue, 20 Oct 2026 08:30:00 -0400

– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw –

– In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and a 99.8% negative predictive value for lung cancer in its intended use population –

BRISBANE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based tests, today announced the launch of SimpleScreen™ Lung and a first-of-its-kind offering that enables eligible patients to be screened for both lung and colorectal cancer (CRC)

Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option

Tue, 20 Oct 2026 08:30:00 -0400

– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw –

– In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and a 99.8% negative predictive value for lung cancer in its intended use population –

Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026

Thu, 15 Oct 2026 16:29:00 -0400

BRISBANE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026, after the market close on Tuesday, November 10, 2026. Following the release, Freenome will host a conference call to discuss its financial results at 1:30 pm Pacific Time / 4:30 pm Eastern Time.

To participate in the conference call, please register here before the start of the call. A live and archived webcast

Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026

Thu, 15 Oct 2026 16:29:00 -0400

To participate in the conference call, please register here before the start of the call. A live and archived webcast

Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026

Sun, 11 Oct 2026 13:00:00 -0400

– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention –

– Overall detection of colorectal cancer remained consistent with test’s first version, achieving 80.4% sensitivity at 90% specificity –

BRISBANE, Calif., Oct. 11, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based tests, today announced the company will present late-breaking data on an updated version of its SimpleScreen™ CRC blood-based screening test at the American College of Gastroenterology (ACG) 2026 Annual Meeting

Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026

Sun, 11 Oct 2026 13:00:00 -0400

– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention –

– Overall detection of colorectal cancer remained consistent with test’s first version, achieving 80.4% sensitivity at 90% specificity –

Form S-8 Freenome, Inc.

Wed, 23 Sep 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260923/27097355.html

Form EFFECT Freenome, Inc.

Fri, 28 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260828/26992634.html

Form EFFECT Freenome, Inc.

Fri, 28 Aug 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260828/26992634.html

Form 424B3 Freenome, Inc.

Thu, 27 Aug 2026 16:30:00 -0400

http://archive.fast-edgar.com/20260827/AK2PG62CZW22MZDA222L2Z42DBINZC22Z282

Filed on: August 27, 2026

Form 424B3 Freenome, Inc.

Thu, 27 Aug 2026 16:30:00 -0400

http://archive.fast-edgar.com/20260827/AK2PG62CZW22MZDA222L2Z42DBINZC22Z282

Filed on: August 27, 2026

Guggenheim Starts Freenome Inc. (FRNM) at Buy

Thu, 20 Aug 2026 06:19:40 -0400

Guggenheim analyst Subbu Nambi initiates coverage on Freenome Inc. (NASDAQ: FRNM) with a Buy rating and a price target of $21.00.

For an analyst ratings summary and ratings history on Freenome Inc. click here. For more ratings news on Freenome Inc. click here.

Shares of Freenome Inc. closed at $13.63 yesterday.

Form S-1 Freenome, Inc.

Tue, 18 Aug 2026 16:52:00 -0400

http://archive.fast-edgar.com/20260818/A82PM22CZW22BJK2222D2Z42IKGLZC22X282

Filed on: August 18, 2026

Form S-1 Freenome, Inc.

Tue, 18 Aug 2026 16:52:00 -0400

http://archive.fast-edgar.com/20260818/A82PM22CZW22BJK2222D2Z42IKGLZC22X282

Filed on: August 18, 2026

TD Cowen Starts Freenome Inc. (FRNM) at Buy

Tue, 18 Aug 2026 05:33:51 -0400

TD Cowen analyst Dan Brennan initiates coverage on Freenome Inc. (NASDAQ: FRNM) with a Buy rating and a price target of $17.00.

The analyst comments "Recently public (via a SPAC) FRNM is anything but 'new' on the scene as the company is well known to investors given its first mover in liquid biopsy (LB) CRC screening. FRNM has differentiated LB chemistry, strong partnerships (ABT, Roche), & a roadmap in MCED and single cancer screening (lung first) that support a sales ramp from $107M in '26 ($7M ex milestone), $242M by '30 & ~$1B by '35."

For an analyst ratings summary and ratings

TD Cowen Starts Freenome Inc. (FRNM) at Buy

Tue, 18 Aug 2026 05:33:51 -0400

TD Cowen analyst Dan Brennan initiates coverage on Freenome Inc. (NASDAQ: FRNM) with a Buy rating and a price target of $17.00.

For an analyst ratings summary and ratings

BTIG Starts Freenome Inc. (FRNM) at Buy

Mon, 17 Aug 2026 05:31:31 -0400

BTIG analyst Mark Massaro initiates coverage on Freenome Inc. (NASDAQ: FRNM) with a Buy rating and a price target of $17.00.

The analyst comments "We initiate coverage of Freenome with a Buy rating and $17 PT. We regard FRNM as a pioneer in blood-based ("liquid biopsy") testing and we believe FRNM is well positioned to become a leader in lung, colon, and multi-cancer early detection (MCED) screening for 10 cancer types. FRNM possesses a blood-based CRC screening test (SimpleScreen) that we think will be competitive to the Cologuard and Shield tests from Abbott (ABT, Buy, $134 PT; Analyst: Marie Thibault) and

BTIG Starts Freenome Inc. (FRNM) at Buy

Mon, 17 Aug 2026 05:31:31 -0400

BTIG analyst Mark Massaro initiates coverage on Freenome Inc. (NASDAQ: FRNM) with a Buy rating and a price target of $17.00.

BTIG Starts Freenome Inc. (FRNM) at Buy

Mon, 17 Aug 2026 05:31:31 -0400

BTIG analyst Mark Massaro initiates coverage on Freenome Inc. (NASDAQ: FRNM) with a Buy rating and a price target of $17.00.

BTIG Starts Freenome Inc. (FRNM) at Buy

Mon, 17 Aug 2026 05:31:31 -0400

BTIG analyst Mark Massaro initiates coverage on Freenome Inc. (NASDAQ: FRNM) with a Buy rating and a price target of $17.00.

Jefferies Starts Freenome Inc. (FRNM) at Buy

Mon, 17 Aug 2026 02:30:51 -0400

Jefferies analyst Tycho Peterson initiates coverage on Freenome Inc. (NASDAQ: FRNM) with a Buy rating and a price target of $17.00.

The analyst comments: “Freenome (FRNM) is developing a portfolio of blood-based cancer screening tests spanning CRC (120M eligible U.S. patients), lung (15M) and 10+ other indications. Leveraging proprietary multi-omics capabilities and partnerships with ABT (CRC only) and ROP-SW (ex-U.S. IVD), we see FRNM as uniquely positioned from a development and commercial standpoint, with a multi-year penetration ramp ahead.

Colorectal cancer screening (CRC) remains the near-term focus, following v1 FDA approval and recent release of v2 data, with a broader ABT-supported commercial

Jefferies Starts Freenome Inc. (FRNM) at Buy

Mon, 17 Aug 2026 02:30:51 -0400

Jefferies analyst Tycho Peterson initiates coverage on Freenome Inc. (NASDAQ: FRNM) with a Buy rating and a price target of $17.00.

Colorectal cancer screening (CRC) remains the near-term focus, following v1 FDA approval and recent release of v2 data, with a broader ABT-supported commercial

Form SCHEDULE 13G/A Freenome, Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260814/26932384.html